Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas6.71 M21.23 M32.55 M33.3 M26.09 M16.68 M18.32 MPesquisa e desenvolvimento13.29 M42.79 M61.46 M93.79 M70.68 M17.5 M24.46 MLucro operacional-20 M-64.02 M-104.02 M-125.47 M-100.9 M-102.27 M-109.94 MLucro não operacional, total-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.43 MDespesa com juros, líquida de juros capitalizados367 K3 000—————Receitas não operacionais, líquidas das despesas com juros-367 K-3 00000000Receitas/despesas incomuns-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.43 MLucro antes dos impostos-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-135.81 MParticipação no lucro———————Impostos-4.3 M-13.5 M-20.4 M-28.3 M-20.7 M0—Participação de minoritários———————Outras receitas/despesas após impostos———————Lucro líquido antes das operações descontinuadas-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MOperações descontinuadas———————Lucro líquido-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MLucro básico por ação——-25.3-30.9-25.2-24.7-24.09Lucro diluído por ação——-25.3-30.9-25.2-24.7-24.09Número médio de ações básicas——3.77 M3.8 M3.85 M4.28 M—Ações diluídas——3.77 M3.8 M3.85 M4.28 M—EBITDA-19.54 M———-100.44 M——EBIT-19.8 M———-100.91 M——Custo da receita———————Outros componentes do custo———————Amortização e depreciação (fluxo de caixa)253 K972 K423 K-445 K455 K643 K436 K
LeonaBio, Inc. - Common Stock
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.